Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.837
-0.024 (-2.81%)
At close: Apr 28, 2026, 4:00 PM EDT
0.837
0.00 (0.00%)
After-hours: Apr 28, 2026, 5:32 PM EDT
Aprea Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aprea Therapeutics stock have an average target of 4.10, with a low estimate of 1.20 and a high estimate of 7.00. The average target predicts an increase of 389.90% from the current stock price of 0.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aprea Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $7 | Buy | Reiterates | $7 | +736.42% | Mar 31, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 → $1.2 | Strong Buy | Maintains | $4 → $1.2 | +43.39% | Mar 31, 2026 |
| Wedbush | Wedbush | Buy Maintains $11 → $7 | Buy | Maintains | $11 → $7 | +736.42% | Feb 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +377.95% | Jan 29, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $5 | Strong Buy | Maintains | $20 → $5 | +497.44% | Dec 18, 2025 |
Financial Forecast
Revenue This Year
n/a
from 285.76K
Revenue Next Year
1.64M
EPS This Year
-0.84
from -1.93
EPS Next Year
-0.69
from -0.84
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 3.4M | ||||||
| Avg | n/a | 1.6M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.79 | -0.48 | |||
| Avg | -0.84 | -0.69 | |||
| Low | -0.88 | -0.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.